Literature DB >> 8614528

Immunoglobulins reactive with myelin basic protein promote CNS remyelination.

M Rodriguez1, D J Miller, V A Lennon.   

Abstract

We tested the hypothesis that immunoglobulins directed against a CNS autoantigen, myelin basic protein, may promote remyelination in the course of a chronic, immune-mediated demyelinating disease. SJL/J mice infected chronically with Daniel's strain of Theiler's virus served as an experimental model of MS. The spinal cords of these mice exhibit extensive primary demyelination and inflammation with minimal spontaneous remyelination. Treatment with whole antiserum or affinity-purified mouse immunoglobulins directed against rat or rabbit myelin basic protein increased new myelin synthesis as measured by quantitative morphometry. Electron microscopy revealed numerous oligodendrocytes in remyelinated CNS lesions and a relative lack of inflammatory cells. Viral antigen persisted in the spinal cord despite enhanced CNS-type remyelination. These findings indicate that immunoglobulins reactive with myelin autoantigens have the potential to promote myelin repair.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614528     DOI: 10.1212/wnl.46.2.538

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  Osmotic demyelination syndrome: variable clinical and radiologic response to intravenous immunoglobulin therapy.

Authors:  Santosh B Murthy; Shahram Izadyar; Megha Dhamne; Joseph S Kass; Corey E Goldsmith
Journal:  Neurol Sci       Date:  2012-04-11       Impact factor: 3.307

Review 3.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 6.  Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury.

Authors:  D P Ankeny; P G Popovich
Journal:  Neuroscience       Date:  2008-07-04       Impact factor: 3.590

7.  Role of γδ T cells in antibody production and recovery from SFV demyelinating disease.

Authors:  Farinaz Safavi; Jason P Feliberti; Cedric S Raine; Foroozan Mokhtarian
Journal:  J Neuroimmunol       Date:  2011-05-25       Impact factor: 3.478

Review 8.  Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.

Authors:  Lisa K Peterson; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2006-12-28       Impact factor: 3.478

9.  Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury.

Authors:  D B McGavern; P D Murray; M Rodriguez
Journal:  J Neurosci Res       Date:  1999-11-15       Impact factor: 4.164

Review 10.  Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

Authors:  Jane M Rodgers; Andrew P Robinson; Stephen D Miller
Journal:  Discov Med       Date:  2013-08       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.